| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1cc4d6ffab1778d0021b8f79793fb40e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 |
| filingDate |
2019-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a86ea7c57962bc97f762ba6a6a72ab4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_375ba1b947541b5a8e32b0c75fe987e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d396f1a7e887fc4ee881151e3cc0b66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_692b4224111b2912e190587b9be72062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f199df477f79101d8cb6f2058367285d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff585001c7787a3f78ae441746c2491f |
| publicationDate |
2020-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020098701-A1 |
| titleOfInvention |
Antibody against staphylococcus aureus α-hemolysin and uses thereof |
| abstract |
Provided are an antibody against staphylococcus aureus α-hemolysin and uses thereof. The CDR of the heavy chain variable region and light chain variable region of said antibody comprises an amino acid sequence (or a functional active CDR variant having the same function) as shown in SEQ ID NO.1-3 or an amino acid sequence (or a functional active CDR variant having the same function) as shown in SEQ ID NO.4-6. Further provided are a nucleic acid molecule for encoding the antibody and uses of the antibody in preparing specific binding staphylococcus aureus α-hemolysin products, staphylococcus aureus vaccines and etc. Moreover, products that can be used as a treatment or adjuvant treatment for staphylococcus aureus infections can be obtained on the basis of the antibody, and finding novel, high efficient and low toxic anti-MRSA drugs become an important direction in recent years for MRES treatment research field. |
| priorityDate |
2018-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |